Bharat Parenterals Limited has made a regulatory disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informs that the National Stock Exchange of India Limited (NSE), through its Circular No. NSE/CML/75748 dated August 14, 2026, has permitted the equity shares of Bharat Parenterals Limited (Symbol: BPLPHARMA) to trade and be admitted to dealings on the Capital Market Segment of NSE with effect from August 17, 2026.
This development means the company's equity shares are now permitted to trade under the "Permitted to Trade" category on NSE, in addition to their existing listing on BSE Limited. The disclosure includes the complete NSE circular as an enclosure.
The NSE circular, issued on August 14, 2026, and effective from August 17, 2026, notifies the admission of securities for dealings on the National Stock Exchange (Capital Market segment) in pursuance of Regulation 3.1.1 of the National Stock Exchange (Capital Market) Trading Regulations Part A. The circular also specifies lot sizes for trading these securities under Regulation 2.5.5 of the same regulations.
The annexure to the circular lists 144 companies whose securities have been admitted to trading, including Bharat Parenterals Limited with symbol BPLPHARMA, ISIN INE365Y01019, face value of ₹10, number of securities 6,891,963, and market lot of 1. Trading in these securities is identified by their designated codes and must comply with the specified lot sizes.
Financial Impact
The disclosure does not quantify any specific financial impact from the NSE listing admission. The move provides additional trading platform accessibility for the company's shares.
Effective Date
August 17, 2026
Place
Vadodara